426268-06-6

Basic information

• Product Name: 4-(8-(benzo[c][1,2,5]oxadiazol-5-yl)-1,7-naphthyridin-6-yl)benzoic acid
• Synonyms: 4-(8-(benzo[c][1,2,5]oxadiazol-5-yl)-1,7-naphthyridin-6-yl)benzoic acid;RO-458,2640;RO-4582640 (4-(8-Benzo[1,2,5]oxadiazol-5-yl-[1,7]naphthyridin-6-yl)-benzoic acid);Benzoic acid, 4-[8-(2,1,3-benzoxadiazol-5-yl)-1,7-naphthyridin-6-yl]-
• CAS NO: 426268-06-6
• Molecular Formula: C₂₁H₁₂N₄O₃
• Molecular Weight: 368.34498
• Mol File: 426268-06-6.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 592.4±60.0 °C(Predicted)
• Appearance: /
• Density: 1.436±0.06 g/cm3(Predicted)
• PKA: 3.87±0.10(Predicted)
• CAS DataBase Reference: 4-(8-(benzo[c][1,2,5]oxadiazol-5-yl)-1,7-naphthyridin-6-yl)benzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(8-(benzo[c][1,2,5]oxadiazol-5-yl)-1,7-naphthyridin-6-yl)benzoic acid(426268-06-6)
• EPA Substance Registry System: 4-(8-(benzo[c][1,2,5]oxadiazol-5-yl)-1,7-naphthyridin-6-yl)benzoic acid(426268-06-6)

Safety Data

• Hazardous Substances Data: 426268-06-6(Hazardous Substances Data)

Usage

Description

4-(8-(Benzo[c][1,2,5]oxadiazol-5-yl)-1,7-naphthyridin-6-yl)benzoic acid is a chemical compound that belongs to the class of benzo[c][1,2,5]oxadiazoles. It is characterized by its unique molecular structure, which features a benzene ring fused with an oxadiazole and a naphthyridine ring. 4-(8-(benzo[c][1,2,5]oxadiazol-5-yl)-1,7-naphthyridin-6-yl)benzoic acid has been found to possess significant biological activities, making it a promising candidate for various pharmaceutical applications.

Uses

Used in Pharmaceutical Industry:
4-(8-(Benzo[c][1,2,5]oxadiazol-5-yl)-1,7-naphthyridin-6-yl)benzoic acid is used as a phosphodiesterase PDE4D inhibitor for the treatment of prostate cancer. It has demonstrated efficacy in both in vitro and in vivo models, making it a potential therapeutic agent for this type of cancer.
Additionally, this compound functions as a phosphodiesterase 4 inhibitor with anti-inflammatory activity. It has the potential for the treatment of airway inflammatory conditions such as asthma and chronic obstructive pulmonary diseases (COPD). By inhibiting phosphodiesterase 4, this compound can help reduce inflammation and improve the symptoms associated with these respiratory conditions.

Upstream product

• 14047-29-1 4-carboxyphenylboronic acid 
• 426268-11-3 trifluoro-methanesulfonic acid 8-benzo[1,2,5]oxadiazol-5-yl-[1,7]naphthyridin-6-yl ester 
• 41153-83-7 6-bromobenzo[c][1,2,5]oxadiazole 1-oxide 
• 426268-10-2 8-benzo[1,2,5]oxadiazol-5-yl-[1,7]naphthyridin-6-ylamine 
• 207279-30-9 6-(4-carboxyphenyl)-8-methoxy-1,7-naphthyridine 
• 207279-29-6 8-methoxy-1,7-naphthyridin-6-yl trifluoromethanesulfonate 
• 426268-09-9 benzo[c][1,2,5]oxadiazole-5-boronic acid 
• 55716-28-4 8-methoxy-[1,7]naphthyridin-6-ylamine 
• 88-74-4 2-nitro-aniline 
• 5912-34-5 2-cyano-pyridin-3-yl-acetonitrile 
• 875-51-4 4-Bromo-2-nitroaniline 
• 5912-35-6 8-bromo-[1,7]naphthyridin-6-ylamine 
• 51376-06-8 5-bromo-benzo[1,2,5]oxadiazole 
• 207279-31-0 6-(4-carboxyphenyl)-8-bromo-1,7-naphthyridine 

Relevant articles and documents

Synthesis of 4-(8-benzo[1,2,5]oxadiazol-5-yl-[1,7]naphthyridine-6-yl)-benzoic acid: A potent and selective phosphodiesterase type 4D inhibitor

The synthesis of a 6,8-disubstituted 1,7-naphthyridine 1 and its characterization as a potent and selective phosphodiesterase type 4D inhibitor (IC50=1.5nM) are described. The compound inhibited TNFα-release from human peripheral blood mononuclear cells and was orally active in a model of adjuvant-induced arthritis in rats.